Be Biopharma (“Be Bio”) is pioneering Engineered B Cell Medicines (BeCM) to dramatically improve patients’ lives who are living with cancer, rare diseases and other serious conditions. The company's medicines address major hurdles of cell and gene therapies, and are durable, re-disable, and can be administered without toxic conditioning, thereby enabling healthcare sectors and patients to treat diseases like cancer, autoimmune conditions, and an enzyme deficiency. Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity. Be Bio was founded in October 2020 by Longwood Fund and B cell engineering pioneers David Rawlings, M.D., and Richard James, Ph.D. from Seattle Children’s Research Institute.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
04/14/2022 | Series B | $118MM | $xx.xx | $280.11MM | ARCH Venture Partners, Bristol Myers Squibb, Atlas Venture, RA Capital Management, Alta Partners, Longwood Fund, Takeda Ventures | |
Price per Share
$xx.xx
Shares Outstanding
117,412,929
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
ARCH Venture Partners, Bristol Myers Squibb, Atlas Venture, RA Capital Management, Alta Partners, Longwood Fund, Takeda Ventures
|
||||||
10/22/2020 | Series A | $64.1MM | $xx.xx | $91.57MM | Atlas Venture, RA Capital Management, Alta Partners, Longwood Fund, Takeda Ventures | |
Price per Share
$xx.xx
Shares Outstanding
95,757,395
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Atlas Venture, RA Capital Management, Alta Partners, Longwood Fund, Takeda Ventures
|